Cutaneous lesions as presentation form of mantle cell lymphoma
Dermatology Reports, 2011 Mantle cell lymphoma is a type of no-Hodgkin lymphoma that affects extranodal areas, especially, bone narrow, digestive tract and Waldeyer ring. Here we report a case of mantle cell lymphoma IV Ann Arbor stage with cutaneous lesions on nasal dorsum and ...
Nayra Merino de Paz +6 more
doaj +1 more source
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Medicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley +1 more source
Small B-Cell Neoplasms With Typical Mantle Cell Lymphoma Immunophenotypes Often Include Chronic Lymphocytic Leukemias [PDF]
, 2008 Albert K. Ho +5 more
openalex +1 more source
Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization [PDF]
, 2023 Dmitry Kazantsev +5 more
openalex +1 more source
New molecular markers in mantle cell lymphoma : studies of cannabinoid receptors, 5-lipoxygenase and SOX11 [PDF]
, 2010 Mantle cell lymphoma (MCL) is a malignant B-cell lymphoma that accounts for 5-10% of all lymphomas and tends to occur in older adults with a higher incidence in males.
Wang, Xiao
core +1 more source
OTO Open, Volume 10, Issue 1, January-March 2026.Abstract Objective Recurrent acute rhinosinusitis (RARS) significantly decreases quality of life. Transplant recipients (TR) are particularly vulnerable to rhinologic conditions. There is a lack of guidelines for managing RARS in this population. Our study aims to determine the prevalence of and risk factors for RARS among TR and assess the need for ...
Estephania Candelo +2 more
wiley +1 more source
Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
Hematology Reports, 2011 The determination of prognosis for B-Non- Hodgkin’s lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells.
Hanan Mohamed Mahmoud +1 more
doaj +1 more source
Fluorescence-based proteasome activity profiling [PDF]
, 2012 With the proteasome emerging as a therapeutic target for cancer treatment, accurate tools for monitoring proteasome (inhibitor) activity are in demand.
Berkers, C.R. +4 more
core +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.ABSTRACT Non‐Hodgkin lymphoma (NHL) is the fifth most common malignancy and accounts for 5% of all cancers in the US, with the largest proportion being B‐cell CD20 positive NHL. Odronextamab is a CD20xCD3 IgG4 bispecific T‐cell‐engaging monoclonal antibody under development for the treatment of relapsed or refractory (R/R) B‐NHL. The objectives of this
Marçal Bravo Padros +5 more
wiley +1 more source
Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase
Brazilian Journal of Medical and Biological Research, 2006 We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and ...
D.M. Matos +4 more
doaj